GlassScriptPhysician profile
Thien Huynh
NPI 1174597108
$10,349.13
in general payments reported to CMS, 2019-2025
34 companies · $2,457 in 2025
The $2,457 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $678 · 2021: $1,462 · 2022: $1,293 · 2023: $1,792 · 2024: $1,786 · 2025: $2,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,013 · Education: $22.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,013.35 |
| Education | $22.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,707.88 | 2019-2025 | Rocklatan, Rhopressa, Hydrus Microstent |
| Abbvie INC. | $1,230.43 | 2022-2025 | |
| Allergan, INC. | $831.42 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $741.49 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $705.72 | 2020-2025 | Acthar |
| Oyster Point Pharma, INC. | $653.78 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $639.44 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Dompe US, INC. | $474.54 | 2020-2025 | Oxervate |
| New World Medical,INC. | $440.24 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $359.32 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $336.08 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $332.89 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $244.14 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $212.25 | 2019-2021 | |
| Harrow Eye, LLC | $208.66 | 2024-2025 | Triesence, Iheezo, Vevye |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $208.22 | 2019-2025 | |
| Horizon Therapeutics Plc | $123.86 | 2021-2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $116.16 | 2024-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Johnson & Johnson Surgical Vision, INC. | $109.80 | 2022-2023 | Tecnis Iol |
| Amgen INC. | $98.33 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $96.88 | 2020-2021 | |
| Shire North American Group INC | $77.09 | 2019 | |
| Sight Sciences, INC. | $70.19 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ani Pharmaceuticals, INC. | $57.76 | 2023-2024 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $55.03 | 2019 | |
| Thea Pharma INC. | $47.35 | 2022-2025 | Iyuzeh |
| Astellas Pharma US INC | $29.36 | 2025 | Izervay |
| Genmab U.S., INC. | $26.78 | 2023 | Tivdak |
| Coopervision INC. | $24.73 | 2024 | Misight Contact Lens |
| Ocular Therapeutix, INC. | $23.75 | 2023 | Dextenza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rxsight INC | $17.25 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Omeros Corporation | $15.86 | 2019 | |
| Eyepoint US, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thien Huynh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.